Base de dados : MEDLINE
Pesquisa : C17.800.174 [Categoria DeCS]
Referências encontradas : 7385 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 739 ir para página                         

  1 / 7385 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29452653
[Au] Autor:Passeron T
[Ad] Endereço:Service de dermatologie, CHU Nice, France; INSERM U1065, équipe 12, C3M, Nice, France. Electronic address: thierry.passeron@unice.fr.
[Ti] Título:[Post-inflammatory hyperpigmentation].
[Ti] Título:L'hyperpigmentation post-inflammatoire..
[So] Source:Ann Dermatol Venereol;143 Suppl 2:S15-S19, 2016 Dec.
[Is] ISSN:0151-9638
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Post-inflammatory hyperpigmentation (PIH) is a hyperpigmentation of the skin occurring after and sometimes during an inflammatory process. Although more frequent in dark skinned individuals, PIH can be observed in any type of skin and at all ages. In most case a strong impact on the quality of life of affected individuals is observed. The pathophysiology of PIH remains largely unknown. The activation of the melanocytes occurs in the first week following the inflammation emphasizing the crucial role of early preventive measures. Photoprotection with balanced UVA and UVB protection is required. Visible light could also play a role in PIH but this remains to be demonstrated. Healing topics with anti-inflammatory properties are of interest after a skin procedure. When the risk of PIH is high or when PIH occurs, topical steroids remains the gold standard approach.
[Mh] Termos MeSH primário: Dermatite/fisiopatologia
Hiperpigmentação/fisiopatologia
[Mh] Termos MeSH secundário: Corticosteroides/administração & dosagem
Dermatite/prevenção & controle
Seres Humanos
Hiperpigmentação/prevenção & controle
Melanócitos/efeitos dos fármacos
Melanócitos/fisiologia
Pigmentação da Pele/efeitos dos fármacos
Pigmentação da Pele/fisiologia
Protetores Solares/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Sunscreening Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180218
[St] Status:MEDLINE


  2 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29179848
[Au] Autor:Palmier S
[Ad] Endereço:Direction des soins, Hôpital Saint Eloi, CHU Montpellier, 80 avenue Augustin Fliche, 34090, Montpellier, France. Electronic address: s-palmier@chu-montpellier.fr.
[Ti] Título:[Treatment of incontinence associated dermatitis].
[Ti] Título:La prise en charge de la dermatite associée à l'incontinence..
[So] Source:Rev Infirm;66(236):40-41, 2017 Dec.
[Is] ISSN:1293-8505
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Incontinence associated dermatitis is one of the main complications of incontinence. Very painful, it is a well-known risk factor of pressure ulcers. Nurse assistants and nurses are on the frontline for detecting and treating the condition.
[Mh] Termos MeSH primário: Dermatite/etiologia
Dermatite/enfermagem
Incontinência Fecal/complicações
Higiene da Pele
Incontinência Urinária/complicações
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE


  3 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463153
[Au] Autor:Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
[Ad] Endereço:Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts; Division of Radiation Oncology, University of Ottawa, Ottawa, Ontario, Canada.
[Ti] Título:Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):344-351, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To analyze immune-related adverse events (ir-AEs) in patients treated with radiation and immune checkpoint blockade. METHODS AND MATERIALS: We retrospectively reviewed records from patients with metastatic non-small cell lung cancer, melanoma, or renal cell cancer who received at least 1 cycle of a CTLA-4 or PD-1 inhibitor and radiation. Immune-related adverse events, defined using Common Terminology Criteria for Adverse Events version 4.0, were tabulated in relation to treatment variables, and associations with sequencing and timing were assessed. RESULTS: We identified 133 patients, of whom 28 received a CTLA-4 inhibitor alone, 88 received a PD-1 inhibitor alone, and 17 received both classes of inhibitors either sequentially (n=13) or concurrently (n=4). Fifty-six patients received radiation within 14 days of an immune checkpoint inhibitor. Forty-six patients experienced at least 1 ir-AE (34.6%). Patients receiving both CTLA-4 and PD-1 inhibitors experienced more any-grade ir-AEs as compared with either individually (71% vs 29%, P=.0008). Any-grade ir-AEs occurred in 39% of patients in whom radiation was administered within 14 days of immunotherapy, compared with 23% of other patients (P=.06) and more often in patients who received higher equivalent dose in 2-Gy fractions (EQD2) EQD2 (P=.01). However, most toxicities were mild. There were no associations between site irradiated and specific ir-AEs. CONCLUSIONS: Our data suggest the combination of focal palliative radiation and CTLA-4 and/or PD-1 inhibitors is well tolerated, with manageable ir-AEs that did not seem to be associated with the particular site irradiated. Although conclusions are limited by the heterogeneity of patients and treatments, and future confirmatory studies are needed, this information can help guide clinical practice for patients receiving immune checkpoint therapy who require palliative radiation therapy.
[Mh] Termos MeSH primário: Antígeno CTLA-4/antagonistas & inibidores
Carcinoma Pulmonar de Células não Pequenas/terapia
Carcinoma de Células Renais/terapia
Pontos de Checagem do Ciclo Celular/imunologia
Imunoterapia/efeitos adversos
Neoplasias Renais/terapia
Neoplasias Pulmonares/terapia
Melanoma/terapia
Receptor de Morte Celular Programada 1/antagonistas & inibidores
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma Pulmonar de Células não Pequenas/secundário
Carcinoma de Células Renais/secundário
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Colite/etiologia
Terapia Combinada/efeitos adversos
Terapia Combinada/métodos
Dermatite/etiologia
Feminino
Seres Humanos
Imunoterapia/métodos
Neoplasias Renais/patologia
Neoplasias Pulmonares/patologia
Masculino
Melanoma/secundário
Meia-Idade
Cuidados Paliativos/métodos
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (CTLA-4 Antigen); 0 (CTLA4 protein, human); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  4 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463230
[Au] Autor:Bagchi S; He Y; Zhang H; Cao L; Van Rhijn I; Moody DB; Gudjonsson JE; Wang CR
[Ad] Endereço:Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
[Ti] Título:CD1b-autoreactive T cells contribute to hyperlipidemia-induced skin inflammation in mice.
[So] Source:J Clin Invest;127(6):2339-2352, 2017 Jun 01.
[Is] ISSN:1558-8238
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A large proportion of human T cells are autoreactive to group 1 CD1 proteins, which include CD1a, CD1b, and CD1c. However, the physiological role of the CD1 proteins remains poorly defined. Here, we have generated a double-transgenic mouse model that expresses human CD1b and CD1c molecules (hCD1Tg) as well as a CD1b-autoreactive TCR (HJ1Tg) in the ApoE-deficient background (hCD1Tg HJ1Tg Apoe-/- mice) to determine the role of CD1-autoreactive T cells in hyperlipidemia-associated inflammatory diseases. We found that hCD1Tg HJ1Tg Apoe-/- mice spontaneously developed psoriasiform skin inflammation characterized by T cell and neutrophil infiltration and a Th17-biased cytokine response. Anti-IL-17A treatment ameliorated skin inflammation in vivo. Additionally, phospholipids and cholesterol preferentially accumulated in diseased skin and these autoantigens directly activated CD1b-autoreactive HJ1 T cells. Furthermore, hyperlipidemic serum enhanced IL-6 secretion by CD1b+ DCs and increased IL-17A production by HJ1 T cells. In psoriatic patients, the frequency of CD1b-autoreactive T cells was increased compared with that in healthy controls. Thus, this study has demonstrated the pathogenic role of CD1b-autoreactive T cells under hyperlipidemic conditions in a mouse model of spontaneous skin inflammation. As a large proportion of psoriatic patients are dyslipidemic, this finding is of clinical significance and indicates that self-lipid-reactive T cells might serve as a possible link between hyperlipidemia and psoriasis.
[Mh] Termos MeSH primário: Antígenos CD1/metabolismo
Dermatite/imunologia
Hiperlipidemias/imunologia
Psoríase/imunologia
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Técnicas de Cocultura
Seres Humanos
Hiperlipidemias/complicações
Ativação Linfocitária
Camundongos Knockout
Infiltração de Neutrófilos
Pele/imunologia
Pele/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD1); 0 (CD1b antigen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180217
[Lr] Data última revisão:
180217
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29264898
[Au] Autor:Arif T; Hassan I; Margoob MA; Anwar P; Shoib S; Akeel S
[Ad] Endereço:Postgraduate department of Dermatology, Sexually Transmitted Diseases, and Leprosy, Government Medical College Srinagar, University of Kashmir, Srinagar, India.
[Ti] Título:Pattern of dermatoses in two groups of admitted psychiatric patients: a cross-sectional study from a tertiary care hospital in Kashmir.
[So] Source:Acta Dermatovenerol Alp Pannonica Adriat;26(4):89-95, 2017 Dec.
[Is] ISSN:1581-2979
[Cp] País de publicação:Slovenia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Various specific and non-specific dermatological manifestations can be found in patients with psychiatric ailments. Most studies in this regard have been conducted on an outpatient basis and not much work has been done on patients admitted with psychiatric diseases. METHODS: This cross-sectional hospital-based study involved two groups of admitted psychiatric patients over a period of 1 year, involving 100 patients in each group. In the family ward group patients were admitted with accompanying family members, whereas in the closed ward group patients were kept under custodial care. RESULTS: In the family ward setting, eczema was the most common finding, observed in 29 patients, followed by atrophic scarring in 28 patients, erythema ab igne in 25 patients, and bacterial infections in five patients. Various forms of nail changes were seen in 18 patients. In the closed ward group, most common dermatological involvement was parasitic infestation, seen in 56 patients, followed by generalized pruritus in 53 patients and atrophic scarring in 52 patients. Thirty-eight patients had nail changes. CONCLUSION: Skin manifestations are more common in chronic neglected psychiatric patients under custodial care. The authors stress upon the importance of familial care provided to psychiatric patients living in custodial settings.
[Mh] Termos MeSH primário: Dermatite/diagnóstico
Transtornos Mentais/diagnóstico
Admissão do Paciente/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Comorbidade
Estudos Transversais
Dermatite/epidemiologia
Feminino
Hospitais Psiquiátricos
Seres Humanos
Índia
Masculino
Transtornos Mentais/epidemiologia
Meia-Idade
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  6 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29040328
[Au] Autor:Peuhu E; Salomaa SI; De Franceschi N; Potter CS; Sundberg JP; Pouwels J
[Ad] Endereço:Turku Centre for Biotechnology, University of Turku, Turku, Finland.
[Ti] Título:Integrin beta 1 inhibition alleviates the chronic hyperproliferative dermatitis phenotype of SHARPIN-deficient mice.
[So] Source:PLoS One;12(10):e0186628, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:SHARPIN (Shank-Associated RH Domain-Interacting Protein) is a component of the linear ubiquitin chain assembly complex (LUBAC), which enhances TNF-induced NF-κB activity. SHARPIN-deficient (Sharpincpdm/cpdm) mice display multi-organ inflammation and chronic proliferative dermatitis (cpdm) due to TNF-induced keratinocyte apoptosis. In cells, SHARPIN also inhibits integrins independently of LUBAC, but it has remained enigmatic whether elevated integrin activity levels in the dermis of Sharpincpdm/cpdm mice is due to increased integrin activity or is secondary to inflammation. In addition, the functional contribution of increased integrin activation to the Sharpincpdm/cpdm phenotype has not been investigated. Here, we find increased integrin activity in keratinocytes from Tnfr1-/- Sharpincpdm/cpdm double knockout mice, which do not display chronic inflammation or proliferative dermatitis, thus suggesting that SHARPIN indeed acts as an integrin inhibitor in vivo. In addition, we present evidence for a functional contribution of integrin activity to the Sharpincpdm/cpdm skin phenotype. Treatment with an integrin beta 1 function blocking antibody reduced epidermal hyperproliferation and epidermal thickness in Sharpincpdm/cpdm mice. Our data indicate that, while TNF-induced cell death triggers the chronic inflammation and proliferative dermatitis, absence of SHARPIN-dependent integrin inhibition exacerbates the epidermal hyperproliferation in Sharpincpdm/cpdm mice.
[Mh] Termos MeSH primário: Proteínas de Transporte/genética
Dermatite/tratamento farmacológico
Epiderme/efeitos dos fármacos
Integrina beta1/genética
Queratinócitos/efeitos dos fármacos
Receptores Tipo I de Fatores de Necrose Tumoral/genética
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/farmacologia
Apoptose
Proteínas de Transporte/imunologia
Proliferação Celular
Doença Crônica
Dermatite/genética
Dermatite/imunologia
Dermatite/patologia
Epiderme/imunologia
Epiderme/patologia
Feminino
Deleção de Genes
Regulação da Expressão Gênica
Inflamação
Integrina beta1/imunologia
Queratinócitos/imunologia
Queratinócitos/patologia
Masculino
Camundongos
Camundongos Knockout
NF-kappa B/genética
NF-kappa B/imunologia
Fenótipo
Receptores Tipo I de Fatores de Necrose Tumoral/deficiência
Receptores Tipo I de Fatores de Necrose Tumoral/imunologia
Transdução de Sinais
Ubiquitina/genética
Ubiquitina/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Carrier Proteins); 0 (Integrin beta1); 0 (NF-kappa B); 0 (Receptors, Tumor Necrosis Factor, Type I); 0 (Sipl1 protein, mouse); 0 (Tnfrsf1a protein, mouse); 0 (Ubiquitin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171018
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186628


  7 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Araújo, Marcelo Grossi
Texto completo SciELO Brasil
[PMID]:28954118
[Au] Autor:Oliveira LML; Souza MV; Guedes ACM; Araújo MG
[Ad] Endereço:Dermatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais - Belo Horizonte(MG), Brazil.
[Ti] Título:Case for diagnosis. Infective dermatitis associated with HTLV-1: differential diagnosis of atopic dermatitis.
[So] Source:An Bras Dermatol;92(4):573-574, 2017 Jul-Aug.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Infective dermatitis associated with HTLV-1 (IDH) is the main cutaneous marker of HTLV-1 infection. This disease occurs primarily in children and should be differentiated from other eczemas, especially from atopic dermatitis. The largest series of IDH are from Jamaica and Brazil. There are an estimated 15 to 20 million infected people in the world, and Brazil is one of the endemic regions. Studies suggest that IDH in children may be a marker for the development of T-cell leukemia/lymphoma (ATL) or myelopathy associated with HTLV-1/tropical spastic paraparesis (HAM / TSP) in adulthood.
[Mh] Termos MeSH primário: Dermatite/diagnóstico
Infecções por HTLV-I/diagnóstico
Dermatopatias Virais/diagnóstico
[Mh] Termos MeSH secundário: Dermatite/virologia
Dermatite Atópica/diagnóstico
Dermatite Atópica/virologia
Diagnóstico Diferencial
Eczema/diagnóstico
Eczema/virologia
Feminino
Infecções por HTLV-I/complicações
Seres Humanos
Leucemia-Linfoma de Células T do Adulto/diagnóstico
Dermatopatias Virais/complicações
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE


  8 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28954102
[Au] Autor:Duarte I; Silveira JEPS; Hafner MFS; Toyota R; Pedroso DMM
[Ad] Endereço:Dermatology Clinic of Santa Casa de Misericórdia de São Paulo - Hospital and School of Medicine- São Paulo (SP), Brazil.
[Ti] Título:Sensitive skin: review of an ascending concept.
[So] Source:An Bras Dermatol;92(4):521-525, 2017 Jul-Aug.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Sensitive skin is a condition characterized by stinging, burning and itching sensations. The diagnosis, pathophysiology and treatment of sensitive skin are still under discussion. In the last years, studies on its epidemiology have been performed, showing a high prevalence and impact on quality of life. Brazilian population was also considered in these studies. Cosmetics, climate changes and skin barrier impairment are the main factors that contribute for skin hyperreactivity. New studies are trying to bring new knowledge about the theme. This review will describe data on epidemiology, triggering factors, pathophysiology, diagnosis and treatment.
[Mh] Termos MeSH primário: Dermatopatias
Distúrbios Somatossensoriais
[Mh] Termos MeSH secundário: Brasil/epidemiologia
Causalidade
Cosméticos/efeitos adversos
Dermatite/diagnóstico
Dermatite/epidemiologia
Dermatite/fisiopatologia
Meio Ambiente
Seres Humanos
Dermatopatias/diagnóstico
Dermatopatias/epidemiologia
Dermatopatias/etiologia
Dermatopatias/terapia
Testes Cutâneos/métodos
Distúrbios Somatossensoriais/diagnóstico
Distúrbios Somatossensoriais/epidemiologia
Distúrbios Somatossensoriais/etiologia
Distúrbios Somatossensoriais/terapia
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cosmetics)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE


  9 / 7385 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28950276
[Au] Autor:Jin Y; Ebaugh S; Martens A; Gao H; Olson E; Ng PKW; Gangur V
[Ad] Endereço:Food Allergy and Immunology Laboratory, Michigan State University, East Lansing, MI, USA.
[Ti] Título:A Mouse Model of Anaphylaxis and Atopic Dermatitis to Salt-Soluble Wheat Protein Extract.
[So] Source:Int Arch Allergy Immunol;174(1):7-16, 2017.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Wheat allergy and other immune-mediated disorders triggered by wheat proteins are growing at an alarming rate for reasons not well understood. A mouse model to study hypersensitivity responses to salt-soluble wheat protein (SSWP) extract is currently unavailable. Here we tested the hypothesis that SSWP extract from wheat will induce sensitization as well as allergic disease in mice. METHODS: Female BALB/cJ mice were weaned onto a plant protein-free diet. The mice were injected a total of 4 times with an SSWP (0.01 mg/mouse) fraction extracted from durum wheat along with alum as an adjuvant. Blood was collected biweekly and SSWP-specific IgE (SIgE) and total IgE (TIgE) levels were measured using ELISA. Systemic anaphylaxis upon intraperitoneal injection with SSWP was quantified by hypothermia shock response (HSR). Mucosal mast cell degranulation was measured by the elevation of mMCP-1 in the blood. The mice were monitored for dermatitis. Skin tissues were used in histopathology and for measuring cytokine/chemokine/adhesion molecule levels using a protein microarray system. RESULTS: Injection with SSWP resulted in time-dependent SIgE antibody responses associated with the elevation of TIgE concentration. Challenge with SSWP elicited severe HSR that correlated with a significant elevation of plasma mMCP-1 levels. Sensitized mice developed facial dermatitis associated with mast cell degranulation. Lesions expressed significant elevation of Th2/Th17/Th1 cytokines and chemokines and E-selectin adhesion molecule. CONCLUSION: Here we report a mouse model of anaphylaxis and atopic dermatitis to SSWP extract that may be used for further basic and applied research on wheat allergy.
[Mh] Termos MeSH primário: Anafilaxia/imunologia
Dermatite Atópica/imunologia
Glutens/imunologia
Triticum/imunologia
Hipersensibilidade a Trigo/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos/sangue
Degranulação Celular/imunologia
Quimases/sangue
Dermatite/imunologia
Modelos Animais de Doenças
Feminino
Imunoglobulina E/sangue
Mastócitos/imunologia
Camundongos
Camundongos Endogâmicos BALB C
Células Th1/imunologia
Células Th17/imunologia
Células Th2/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 37341-29-0 (Immunoglobulin E); 8002-80-0 (Glutens); EC 3.4.21.39 (Chymases); EC 3.4.21.39 (Mcpt1 protein, mouse)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170927
[St] Status:MEDLINE
[do] DOI:10.1159/000479386


  10 / 7385 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28917452
[Au] Autor:Chaowattanapanit S; Silpa-Archa N; Kohli I; Lim HW; Hamzavi I
[Ad] Endereço:Department of Dermatology, Henry Ford Hospital, Detroit, Michigan; Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
[Ti] Título:Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention.
[So] Source:J Am Acad Dermatol;77(4):607-621, 2017 Oct.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Postinflammatory hyperpigmentation (PIH) occurs after various dermatoses, exogenous stimuli, and dermatologic procedures. The clinical course of PIH is chronic and unpredictable, although the probability of resolution of epidermal hyperpigmentation is better than those of dermal hyperpigmentation. PIH can be prevented or alleviated. When it does occur, the underlying inflammatory conditions should be sought and treated as the first step to reduce the progression of inflammation and PIH (which is an inflammatory consequence). If the inflammatory conditions subsides or there is no evidence of inflammation at the time of diagnosis, the treatments of PIH should be considered as the next step. Understanding the available treatment options helps the physician choose the appropriate treatment for each patient. Having a reproducible model for PIH is essential for the development of treatment modalities. The second article in this 2-part continuing medical education series on PIH specifically addresses the evidence that supports medical and procedural treatments of PIH and other forms of acquired hyperpigmentation. It also describes a PIH model and provides an algorithm for clinical practice along with discussion about the prevention of PIH.
[Mh] Termos MeSH primário: Dermatite/complicações
Fármacos Dermatológicos/uso terapêutico
Hiperpigmentação/terapia
Preparações Clareadoras de Pele/uso terapêutico
[Mh] Termos MeSH secundário: Antioxidantes/uso terapêutico
Abrasão Química
Combinação de Medicamentos
Seres Humanos
Hidroquinonas/uso terapêutico
Hiperpigmentação/prevenção & controle
Terapia a Laser
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antioxidants); 0 (Dermatologic Agents); 0 (Drug Combinations); 0 (Hydroquinones); 0 (Skin Lightening Preparations); XV74C1N1AE (hydroquinone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170918
[St] Status:MEDLINE



página 1 de 739 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde